Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-03-24 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares). The text explicitly details transactions on Sanofi's own shares (rachats d'actions) executed between March 17, 2025, and March 21, 2025, including aggregated daily volumes, weighted average prices, and a detailed transaction log. This content directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance).
2025-03-24 French
Communiqué de presse : Mise en ligne du document « Q1 2025 Aide mémoire »
Report Publication Announcement Classification · 98% confidence The document is a press release ("Communiqué de presse") dated March 24, 2025, announcing the online posting ("Mise en ligne") of a document titled "Q1 2025 Aide mémoire" (Q1 2025 Memorandum). It explicitly states that this document is intended to assist the financial community in modeling quarterly results and contains reminders about non-recurring items, currency effects, and share count. Crucially, it mentions that the actual Q1 2025 results will be announced later (April 24, 2025). Since this document is an announcement about the availability of supplementary material (the 'Aide mémoire') rather than the primary financial report (like ER or IR) itself, and it is a formal announcement regarding the publication of a report/material, it fits the definition of a Report Publication Announcement (RPA). The document length is moderate (5940 chars), but the content is purely an announcement of publication, aligning with the 'MENU VS MEAL' rule.
2025-03-24 French
Press Release: Availability of the Q1 2025 Aide mémoire
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "Press Release" and announces the "Availability of the Q1 2025 Aide mémoire." It states that the Q1 2025 results will be published later (April 24, 2025) and that the Aide mémoire document is available now to assist in financial modelling. This structure—a short announcement stating that a specific report (the Aide mémoire) is now available—fits the definition of a Report Publication Announcement (RPA). It is not the full earnings release (ER) or the comprehensive interim report (IR), but the announcement *about* the availability of supporting material for those reports. The document length (5545 chars) is consistent with a brief announcement rather than a full financial report.
2025-03-24 English
S-8 POS
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-8 filed with the SEC. It pertains to deregistration of certain shares under the Action 2024 Shareholding Plan. Form S-8 is used for securities registration related to employee benefit plans. The document is a regulatory filing about share registration and deregistration, not a financial report or earnings release. It is also short (3452 characters) and serves as an official amendment to a prior registration statement. Therefore, it fits best under Transaction in Own Shares (POS), which covers share repurchase/issuance and related filings.
2025-03-21 English
6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release about an acquisition (Sanofi acquiring Dren Bio's bispecific myeloid cell engager). The document is short (1336 characters) and primarily serves as an announcement of the press release rather than containing detailed financial data or the full report itself. The content relates to a merger/acquisition activity announcement. Therefore, the most appropriate classification is M&A Activity (TAR).
2025-03-20 English
Communiqué de presse : Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en im
Capital/Financing Update Classification · 95% confidence The document is a press release ("Communiqué de presse") dated March 20, 2025, announcing that Sanofi has entered into a definitive agreement to acquire Dren Bio, Inc., specifically its asset DR-0201, for an upfront payment plus potential future milestones. This describes a corporate transaction involving financing/acquisition activity. Reviewing the definitions, the 'Capital/Financing Update (CAP)' category covers 'Updates on company fundraising, financing activities, or capital structure changes.' While this is an acquisition, the core event described is a major financing/transaction activity. It is not a standard 10-K, ER, or IR. It is most closely aligned with CAP, as it details the financial terms of acquiring a new asset/company. It is not a merger/takeover bid (TAR) in the sense of a hostile bid, but a strategic acquisition, which often falls under CAP or sometimes TAR, but CAP seems more appropriate for the financing aspect detailed. Given the focus on the financial terms ($600M upfront + $1.3B milestones) and the nature of the deal (acquiring an asset/subsidiary), CAP is the best fit among the provided options for a significant corporate financing/transaction announcement.
2025-03-20 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.